TY - JOUR
T1 - Treatment of central disorders of hypersomnolence
T2 - An American Academy of Sleep Medicine clinical practice guideline
AU - Maski, Kiran
AU - Trotti, Lynn Marie
AU - Kotagal, Suresh
AU - Auger, R. Robert
AU - Rowley, James A.
AU - Hashmi, Sarah D.
AU - Watson, Nathaniel F.
N1 - Publisher Copyright:
Copyright 2021 American Academy of Sleep Medicine. All rights reserved.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Introduction: This guideline establishes clinical practice recommendations for the treatment of central disorders of hypersomnolence in adults and children. Methods: The American Academy of Sleep Medicine commissioned a task force of experts in sleep medicine to develop recommendations and assign strengths to each recommendation, based on a systematic review of the literature and an assessment of the evidence using the GRADE process. The task force provided a summary of the relevant literature and the quality of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations that support the recommendations. The AASM Board of Directors approved the final recommendations. Recommendations: The following recommendations are intended to guide clinicians in choosing a specific treatment for central disorders of hypersomnolence in adults and children. Each recommendation statement is assigned a strength (“strong” or “conditional”). A “strong” recommendation (ie, “We recommend …”) is one that clinicians should follow under most circumstances. A “conditional” recommendation (ie, “We suggest …”) is one that requires that the clinician use clinical knowledge and experience and strongly consider the individual patient’s values and preferences to determine the best course of action. Under each disorder, strong recommendations are listed in alphabetical order followed by the conditional recommendations in alphabetical order. The section on adult patients with hypersomnia because of medical conditions is categorized based on the clinical and pathological subtypes identified in ICSD-3. The interventions in all the recommendation statements were compared to no treatment. Adult patients with narcolepsy 1. We recommend that clinicians use modafinil for the treatment of narcolepsy in adults. (STRONG) 2. We recommend that clinicians use pitolisant for the treatment of narcolepsy in adults. (STRONG) 3. We recommend that clinicians use sodium oxybate for the treatment of narcolepsy in adults. (STRONG) 4. We recommend that clinicians use solriamfetol for the treatment of narcolepsy in adults. (STRONG) 5. We suggest that clinicians use armodafinil for the treatment of narcolepsy in adults. (CONDITIONAL) 6. We suggest that clinicians use dextroamphetamine for the treatment of narcolepsy in adults. (CONDITIONAL) 7. We suggest that clinicians use methylphenidate for the treatment of narcolepsy in adults. (CONDITIONAL) Adult patients with idiopathic hypersomnia 8. We recommend that clinicians use modafinil for the treatment of idiopathic hypersomnia in adults. (STRONG) 9. We suggest that clinicians use clarithromycin for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL) 10. We suggest that clinicians use methylphenidate for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL) 11. We suggest that clinicians use pitolisant for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL) 12. We suggest that clinicians use sodium oxybate for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL) Adult patients with Kleine-Levin syndrome 13. We suggest that clinicians use lithium for the treatment of Kleine-Levin syndrome in adults. (CONDITIONAL) Adult patients with hypersomnia due to medical conditions Hypersomnia secondary to alpha-synucleinopathies 14. We suggest that clinicians use armodafinil for the treatment of hypersomnia secondary to dementia with Lewy bodies in adults. (CONDITIONAL) 15. We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to Parkinson’s disease in adults. (CONDITIONAL) 16. We suggest that clinicians use sodium oxybate for the treatment of hypersomnia secondary to Parkinson’s disease in adults. (CONDITIONAL) Posttraumatic hypersomnia 17. We suggest that clinicians use armodafinil for the treatment of hypersomnia secondary to traumatic brain injury in adults. (CONDITIONAL) 18. We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to traumatic brain injury in adults. (CONDITIONAL) Adult patients with genetic disorders associated with primary central nervous system somnolence 19. We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to myotonic dystrophy in adults. (CONDITIONAL) Adult patients with hypersomnia secondary to brain tumors, infections, or other central nervous system lesions 20. We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to multiple sclerosis in adults. (CONDITIONAL) Pediatric patients with narcolepsy 21. We suggest that clinicians use modafinil for the treatment of narcolepsy in pediatric patients. (CONDITIONAL) 22. We suggest that clinicians use sodium oxybate for the treatment of narcolepsy in pediatric patients. (CONDITIONAL).
AB - Introduction: This guideline establishes clinical practice recommendations for the treatment of central disorders of hypersomnolence in adults and children. Methods: The American Academy of Sleep Medicine commissioned a task force of experts in sleep medicine to develop recommendations and assign strengths to each recommendation, based on a systematic review of the literature and an assessment of the evidence using the GRADE process. The task force provided a summary of the relevant literature and the quality of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations that support the recommendations. The AASM Board of Directors approved the final recommendations. Recommendations: The following recommendations are intended to guide clinicians in choosing a specific treatment for central disorders of hypersomnolence in adults and children. Each recommendation statement is assigned a strength (“strong” or “conditional”). A “strong” recommendation (ie, “We recommend …”) is one that clinicians should follow under most circumstances. A “conditional” recommendation (ie, “We suggest …”) is one that requires that the clinician use clinical knowledge and experience and strongly consider the individual patient’s values and preferences to determine the best course of action. Under each disorder, strong recommendations are listed in alphabetical order followed by the conditional recommendations in alphabetical order. The section on adult patients with hypersomnia because of medical conditions is categorized based on the clinical and pathological subtypes identified in ICSD-3. The interventions in all the recommendation statements were compared to no treatment. Adult patients with narcolepsy 1. We recommend that clinicians use modafinil for the treatment of narcolepsy in adults. (STRONG) 2. We recommend that clinicians use pitolisant for the treatment of narcolepsy in adults. (STRONG) 3. We recommend that clinicians use sodium oxybate for the treatment of narcolepsy in adults. (STRONG) 4. We recommend that clinicians use solriamfetol for the treatment of narcolepsy in adults. (STRONG) 5. We suggest that clinicians use armodafinil for the treatment of narcolepsy in adults. (CONDITIONAL) 6. We suggest that clinicians use dextroamphetamine for the treatment of narcolepsy in adults. (CONDITIONAL) 7. We suggest that clinicians use methylphenidate for the treatment of narcolepsy in adults. (CONDITIONAL) Adult patients with idiopathic hypersomnia 8. We recommend that clinicians use modafinil for the treatment of idiopathic hypersomnia in adults. (STRONG) 9. We suggest that clinicians use clarithromycin for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL) 10. We suggest that clinicians use methylphenidate for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL) 11. We suggest that clinicians use pitolisant for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL) 12. We suggest that clinicians use sodium oxybate for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL) Adult patients with Kleine-Levin syndrome 13. We suggest that clinicians use lithium for the treatment of Kleine-Levin syndrome in adults. (CONDITIONAL) Adult patients with hypersomnia due to medical conditions Hypersomnia secondary to alpha-synucleinopathies 14. We suggest that clinicians use armodafinil for the treatment of hypersomnia secondary to dementia with Lewy bodies in adults. (CONDITIONAL) 15. We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to Parkinson’s disease in adults. (CONDITIONAL) 16. We suggest that clinicians use sodium oxybate for the treatment of hypersomnia secondary to Parkinson’s disease in adults. (CONDITIONAL) Posttraumatic hypersomnia 17. We suggest that clinicians use armodafinil for the treatment of hypersomnia secondary to traumatic brain injury in adults. (CONDITIONAL) 18. We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to traumatic brain injury in adults. (CONDITIONAL) Adult patients with genetic disorders associated with primary central nervous system somnolence 19. We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to myotonic dystrophy in adults. (CONDITIONAL) Adult patients with hypersomnia secondary to brain tumors, infections, or other central nervous system lesions 20. We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to multiple sclerosis in adults. (CONDITIONAL) Pediatric patients with narcolepsy 21. We suggest that clinicians use modafinil for the treatment of narcolepsy in pediatric patients. (CONDITIONAL) 22. We suggest that clinicians use sodium oxybate for the treatment of narcolepsy in pediatric patients. (CONDITIONAL).
UR - http://www.scopus.com/inward/record.url?scp=85114248660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114248660&partnerID=8YFLogxK
U2 - 10.5664/jcsm.9328
DO - 10.5664/jcsm.9328
M3 - Review article
C2 - 34743789
AN - SCOPUS:85114248660
SN - 1550-9389
VL - 17
SP - 1881
EP - 1893
JO - Journal of Clinical Sleep Medicine
JF - Journal of Clinical Sleep Medicine
IS - 9
ER -